KDC44301
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim., PMID:40468685
Granulocyte colony-stimulating factor-associated aortitis in a man with advanced prostate cancer., PMID:40336734
Is it appropriate to select patients for primary prophylactic use of pegfilgrastim based on the risk of febrile neutropenia?, PMID:40332472
Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma., PMID:40281003
Large vessel vasculitis associated with atezolizumab., PMID:40268701
Efficacy and Safety of Pegylated Filgrastim as Primary Prophylaxis Following Pediatric Dose-intensive Chemotherapy: A Randomized Controlled Trial., PMID:40202126
Polyostotic Langerhans cell histiocytosis presenting as halitosis in a 24-year-old man: a case report., PMID:40181439
Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer., PMID:40155019
Caught in the Crossfire: A Case of Splenic Infarction Amid G-CSF therapy in Chronic Myelomonocytic Leukaemia., PMID:40051744
Optimizing biosimilar development: current approaches to demonstrating pharmacokinetic and analytical similarity and a proposal for a single reference approach., PMID:40035204
Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management., PMID:40019675
Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma., PMID:39983375
Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information., PMID:39951116
Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022., PMID:39934515
Cross-sectional patient survey of biological medicine users in Finland to investigate the types of guidance needed by patients in order to carry out their treatment successfully., PMID:39819919
Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma., PMID:39748616
Literature review analysis of aortitis induced by granulocyte-colony stimulating factor., PMID:39744136
Scaling analytical RP-HPLC to semi-preparative for fractionation and characterization of pegfilgrastim oxidized variants., PMID:39689576
Candida Epiglottitis in a Patient Undergoing Chemotherapy for Small Cell Lung Cancer: A Case Report., PMID:39610630
Chronic g-CSF increases the neutrophil-lymphocyte ratio and decreases plasma corticosterone concentrations in Peromyscus maniculatus without impacting compulsive-like stereotypy., PMID:39608238
IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents., PMID:39531584
Aggregation of human plasma and of human blood induced in vitro by pegfilgrastim originator formulation buffer and pegfilgrastim products., PMID:39492447
[Investigation of the Changes in Blood Cell Components following the Administration of Pegfilgrastim in Neo-Adjuvant and Adjuvant FEC Chemotherapy for Breast Cancer]., PMID:39462626
Demonstration of physicochemical and functional similarity between Stimufend (pegfilgrastim-fpgk) and Neulasta (pegfilgrastim): A comparative analytical assessment., PMID:39446813
Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia., PMID:39436413
Clinical effect of prophylactic pegfilgrastim in patients with newly diagnosed acute lymphoblastic leukemia who receive intensive chemotherapy., PMID:39377915
A retrospective single institutional analysis of outpatient chemotherapy in patients with cancer during the COVID-19 pandemic., PMID:39219586
Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study., PMID:39218657
Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden., PMID:39209867
[The Utility of Primary Prophylaxis with Pegfilgrastim in Combination with Polatuzumab Vedotin Therapy]., PMID:39191692
[Approaches and Challenges in the Clinical Application of On-Body Injector(G-Lasta BodyPod)]., PMID:39191689
Differential impact of pegfilgrastim, a recombinant human granulocyte colony stimulating factor, on the neutrophil count of male and female deer mice (Peromyscus maniculatus bairdii)., PMID:39160640
Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study., PMID:39148050
Ryzneuta for prevention of febrile neutropenia., PMID:39137176
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis., PMID:39131872
A Case of Revelation Due to Pegfilgrastim., PMID:39100048
A retrospective study on the efficacy of pegfilgrastim-filgrastim combination regimen in the mobilization for autologous stem cell transplantation in lymphoma patients., PMID:39089426
Biosimilar underutilization alone does not foretell a broken biologics market., PMID:39071106
Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography revealed the course of granulocyte-colony stimulating factor-associated aortitis: A case report., PMID:39050642
Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer., PMID:39009900
[A Case of Granulocyte Colony-Stimulating Factor-Related Aortitis that Developed during the Treatment of Advanced Prostate Cancer with Neuroendocrine Differentiation]., PMID:38967031
Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications - an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis., PMID:38962838
Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer., PMID:38961545
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim., PMID:38958918
Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial., PMID:38925586
On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status., PMID:38865836
Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan., PMID:38857244
Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19., PMID:38843282
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
